<code id='71082CD044'></code><style id='71082CD044'></style>
    • <acronym id='71082CD044'></acronym>
      <center id='71082CD044'><center id='71082CD044'><tfoot id='71082CD044'></tfoot></center><abbr id='71082CD044'><dir id='71082CD044'><tfoot id='71082CD044'></tfoot><noframes id='71082CD044'>

    • <optgroup id='71082CD044'><strike id='71082CD044'><sup id='71082CD044'></sup></strike><code id='71082CD044'></code></optgroup>
        1. <b id='71082CD044'><label id='71082CD044'><select id='71082CD044'><dt id='71082CD044'><span id='71082CD044'></span></dt></select></label></b><u id='71082CD044'></u>
          <i id='71082CD044'><strike id='71082CD044'><tt id='71082CD044'><pre id='71082CD044'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:5
          Chemotherapy infusion
          The White House outlined its efforts to end shortages of three key generic chemotherapies. But experts want more more details. Gerry Broome/AP

          WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. But experts said the administration would have to provide more details to fully mitigate the health care system’s concerns.

          Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States. They have been staples of cancer treatment for decades, according to a White House blog post, but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.

          advertisement

          In its blog post, the White House noted that it’s now allowing Chinese imports of cisplatin. The Food and Drug Administration is also working with generic drug companies to boost production of all three drugs, but it didn’t say which companies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Disclosing genetic information: not as worrisome as once feared
          Disclosing genetic information: not as worrisome as once feared

          AdobeWhentheHumanGenomeProjectbeganin1990,bioethicistsfearedthatgivingpeopletheresultsofgenetictests

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

          ChristineKao/STATTheFoodandDrugAdministration’sapprovalonFridayoftwogenetherapiesforsicklecelldiseas